乳腺癌病人应用帕妥珠单抗 曲妥珠单抗双靶向治疗 卡培他滨获利吗?

  • A+
所属分类:医疗资讯

乳腺癌病人应用帕妥珠单抗 曲妥珠单抗双靶向治疗 卡培他滨获利吗? 。
卡培他滨摘 要:卡培他滨片何时吃好。乳腺癌病人应用帕妥珠单抗 曲妥珠单抗双靶向治疗 卡培他滨获利吗?英国《临床肿瘤杂志》2022年4月24日线上先给h乳腺癌病人应用帕妥珠单抗 曲妥珠单抗双靶向治疗 卡培他滨获利吗?ttp://ascopubs.org/doi/abs/10.1200/JCO.2016.70.6267

外皮细胞生长因子蛋白激酶2呈阳性的迁移扩散性乳腺癌病患者在曲妥珠单抗为基本的医治时间范围或医治后发生病况进度后采用曲妥珠单抗加卡培他滨协同或不协同帕妥珠单抗的任意III期实验

目地在外皮细胞生长因子蛋白激酶2呈阳性的迁移扩散性乳腺癌病患者中,针对已进行过紫衫药物医治、且在曲妥珠单抗为基本的医治时间范围或医治后发生病况进度后的病患者,评定曲妥珠单抗加卡培他滨协同或不协同帕妥珠单抗的有效和安全防护特点。病患者和办法将病患者任意分派到A组:曲妥珠单抗8mg/kg→6mg/kg、每3周1次,加卡培他滨1250mg/m2、每日2次(服食2周停1周,每3周反复);或任意分派到B组:帕妥珠单抗840mg→420mg、每3周1次,+与A组一样使用量和应用药時间的曲妥珠单抗+与A组一样应用药時间的卡培他滨1000mg/m2。关键终端为单独审查组织评定的无进度存活(IRF PFS)。主次终点站包含总存活(OS)和安全防护特点。选用分层次检测方式 操纵对单独审查组织评定的无进度存活、总存活和客观缓解率开展统计分析检测时的I型不正确。結果任意分派(意向医治)到A组和B组的病患者各自为224、228例。在中国位随诊28.6、25.3个月时的负相关IRF PFS为9.0较为11.一个月(风险比,0.82;95%CI,0.65-1.02;P=0.0731),中后期OS为28.1较为36.一个月(风险比,0.68;95%CI,0.51-0.90)。最普遍的欠佳(过虑词)(全部等级的欠佳(过虑词);2组发病率均≥10%,且2组相距≥5%),A组为手足综合征、恶心想吐和单核细胞降低,B组是拉肚子、疹子和鼻咽炎。结果将帕妥珠单抗添加曲妥珠单抗和卡培他滨方式 中并没有明显改进IRF PFS,但留意到,帕妥珠单抗能使负相关总存活時间提升8个月至36.一个月。因为是在关键终点站无进度存活時间以后完成的总存活时长的分层次检测,因而不可以肯定总存活时长的统计学意义,但总存活时长的差别环节与以前帕妥珠单抗医治迁移扩散性乳腺癌的数据信息一致。沒有发觉新的安全性特点信息内容。http://ascopubs.org/doi/abs/10.1200/JCO.2016.70.6267

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy

PurposeTo assess the efficacy and safety of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy and received a prior taxane.Patients and MethodsPatients were randomly assigned to arm A: trastuzumab 8 mg/kg →乳腺癌病人应用帕妥珠单抗 曲妥珠单抗双靶向治疗 卡培他滨获利吗? 6 mg/kg once every 3 weeks plus capecitabine 1,250 mg/m2 twice a day (2 weeks on, 1 week off, every 3 weeks); or arm B: pertuzumab 840 mg → 420 mg once every 3 weeks plus trastuzumab at the same dose and schedule as arm A plus capecitabine 1,000 mg/m2 on the same schedule as arm A. The primary end point was independent review facility–assessed progression-free survival (IRF PFS). Secondary end points included overall survival (OS) and safety. Hierarchical testing procedures were used to control type I error for statistical testing of IRF PFS, OS, and objective response rate.ResultsRandomly assigned (intent-to-treat) populations were 224 and 228 patients in arms A and B, respectively. Median IRF PFS at 28.6 and 25.3 months’ median follow-up was 9.0 v 11.1 months (hazard ratio, 0.82; 95% CI, 0.65 to 1.02; P = .0731) and interim OS was 28.1 v 36.1 months (hazard ratio, 0.68; 95% CI, 0.51 to 0.90). The most common adverse events (all grades; incidence of ≥ 10% in either arm and ≥ 5% difference between arms) were hand-foot syndrome, nausea, and neutropenia in arm A, and diarrhea, rash, and nasopharyngitis in arm B.ConclusionThe addition of pertuzumab to trastuzumab and capecitabine did not significantly improve IRF PFS. An 8-month increase in median OS to 36.1 months with pertuzumab was observed. Statistical significance for OS cannot be claimed because of the hierarchical testing of OS after the primary PFS end point; however, the magnitude of OS difference is in keeping with prior experience of pertuzumab in metastatic breast cancer. No new safety signals were identified.《壹篇》王津京《壹篇》系关键朝向医护人员的服务性【微信号码:yaodaoyaofang】,不因盈利为目地,不开展一切有偿服务资询和服务项目,不销售一切商品,与ASCO、CSCO等全部技术专业学好和组织并没有任何的关联和联络,都不意味着一切官方网学好发音。文章照片均来源于互联网,不做商业行为,若有著作权异议请与《壹篇》联络。不断关注点赞——【手机微信:india2080】、称赞和分享——【手机微信:india2080】是一种心态和适用。
经济发展找药,助推性命。卡培他滨印度的全世界海淘药店:贝伐珠单抗加卡培他滨计划方案。

  • 微信咨询
  • 这是我的微信扫一扫
  • weinxin
  • WhatsApp 沟通
  • 手机扫一扫二维码
  • weinxin

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: